Potent and selective oxytocin receptor agonists without disulfide bridges.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2017.04.030PMID 28438540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New, potent, and selective peptidic oxytocin receptor agonists.

  2014cited by this paper
• Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non‐peptide oxytocin receptor agonist WAY 267,464: a biotelemetry study in rats

  2014cited by this paper
• Oxytocin administration enhances controlled social cognition in patients with schizophrenia.

  2014cited by this paper
• The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor‐Binding Profile, Prosocial Effects and Distribution of c‐Fos Expression in Adolescent Rats

  2012cited by this paper
• Serum stability of selected decapeptide agonists of KISS1R using pseudopeptides.

  2012cited by this paper
• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  2012cited by this paper
• Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

  2010cited by this paper
• Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist.

  2010cited by this paper
• The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.

  2010cited by this paper
• Oxytocin, vasopressin, and human social behavior.

  2009cited by this paper
• Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior.

  2009cited by this paper
• Opposite effects of oxytocin and vasopressin on the emotional expression of the fear response.

  2008cited by this paper
• Oxytocin increases retention of social cognition in autism.

  2007cited by this paper
• The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study.

  2005cited by this paper
• The oxytocin receptor.

  2003cited by this paper
• The oxytocin receptor system: structure, function, and regulation.

  2001cited by this paper
• Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis.

  1999cited by this paper
• Plasma oxytocin levels in autistic children.

  1998cited by this paper
• A neurobiological basis of social attachment.

  1997cited by this paper
• Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.

  1983cited by this paper
• Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10.

  1978cited by this paper
• Replacement of the disulfide bond in oxytocin by an amide group. Synthesis and some biological properties of (cyclo-(1-L-aspartic acid,6-L-alpha,beta-diaminopropionic acid))oxytocin.

  1978cited by this paper
• REPLACEMENT OF THE DISULFIDE BOND IN OXYTOCIN BY AN AMIDE GROUP. SYNTHESIS AND SOME BIOLOGICAL PROPERTIES OF (CYCLO-(1-L-ASPARTIC ACID 6-L-α,β-DIAMINOPROPIONIC ACID))OXYTOCIN

  1978cited by this paper
• Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones

  1976cited by this paper
• Oxytocin analogues with combined high smooth muscle and negligible antidiuretic activities. Investigation of position 7 in neurohypophyseal hormones.

  1976cited by this paper
• Pharmacology of cyclic analogues of deamino-oxytocin not containing a disulphide bond (carba analogues).

  1973cited by this paper
• A highly potent analogue of oxytocin, desamino-oxytocin.

  1962cited by this paper
• The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin.

  1953cited by this paper

• No Measurable Transfer of Oxytocin-Receptor Agonist Merotocin Detected in Human Breast Milk

  2024cites this paper
• Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers

  2024cites this paper
• Identification of three elevenin receptors and roles of elevenin disulfide bond and residues in receptor activation in Aplysia californica

  2023cites this paper
• Characterization of an Aplysia vasotocin signaling system and actions of posttranslational modifications and individual residues of the ligand on receptor activity

  2023cites this paper
• Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate

  2022cites this paper
• α-Conotoxin Peptidomimetics: Probing the Minimal Binding Motif for Effective Analgesia

  2020cites this paper
• Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.

  2020cites this paper
• Design of Oxytocin Analogs.

  2019cites this paper
• Cyclic Peptide Design

  2019cites this paper
• Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.

  2019cites this paper
• LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.

  2018cites this paper
• Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.

  2017cites this paper